Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Duchenne and Myotonic Dystrophy Programs

Reuters12-16

Entrada <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Unveils Pipeline Progress and Clinical Milestones for Duchenne and Myotonic Dystrophy Programs

Entrada Therapeutics Inc. has provided an update on its clinical development pipeline, outlining plans to advance four clinical-stage programs by the end of 2025. Key milestones expected in 2026 include data readouts for ENTR-601-44 and ENTR-601-45, as well as progress on ENTR-601-50 and Vertex-partnered VX-670 for myotonic dystrophy type 1 (DM1). The company highlighted its strategy around its EEV platform, emphasizing improvements in endosomal escape and the development of novel PMO conjugates. Entrada also noted that ongoing and planned ex-U.S. studies are designed to generate data supporting future regulatory discussions and potential accelerated approval pathways. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on December 15, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591962511?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 01:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591962511","market":"nz","top_or_hot":-1,"title":"Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Duchenne and Myotonic Dystrophy Programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline Progress and Clinical Milestones for Duchenne and Myotonic Dystrophy Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Entrada Therapeutics Inc. has provided an update on its clinical development pipeline, outlining plans to advance four clinical-stage programs by the end of 2025. Key milestones expected in 2026 include data readouts for ENTR-601-44 and ENTR-601-45, as well as progress on ENTR-601-50 and Vertex-partnered VX-670 for myotonic dystrophy type 1 (DM1). The company highlighted its strategy around its EEV platform, emphasizing improvements in endosomal escape and the development of novel PMO conjugates. Entrada also noted that ongoing and planned ex-U.S. studies are designed to generate data supporting future regulatory discussions and potential accelerated approval pathways. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Duchenne and Myotonic Dystrophy Programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEntrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Duchenne and Myotonic Dystrophy Programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-16 01:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Unveils Pipeline Progress and Clinical Milestones for Duchenne and Myotonic Dystrophy Programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Entrada Therapeutics Inc. has provided an update on its clinical development pipeline, outlining plans to advance four clinical-stage programs by the end of 2025. Key milestones expected in 2026 include data readouts for ENTR-601-44 and ENTR-601-45, as well as progress on ENTR-601-50 and Vertex-partnered VX-670 for myotonic dystrophy type 1 (DM1). The company highlighted its strategy around its EEV platform, emphasizing improvements in endosomal escape and the development of novel PMO conjugates. Entrada also noted that ongoing and planned ex-U.S. studies are designed to generate data supporting future regulatory discussions and potential accelerated approval pathways. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on December 15, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251215:nNDLG6xjk:1","article_id":"2591962511","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591962511","pubTimestamp":1765820739,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Entrada Therapeutics Inc. has provided an update on its clinical development pipeline, outlining plans to advance four clinical-stage programs by the end of 2025. Key milestones expected in 2026 include data readouts for ENTR-601-44 and ENTR-601-45, as well as progress on ENTR-601-50 and Vertex-partnered VX-670 for myotonic dystrophy type 1 . The company highlighted its strategy around its EEV platform, emphasizing improvements in endosomal escape and the development of novel PMO conjugates. Entrada also noted that ongoing and planned ex-U.S. studies are designed to generate data supporting future regulatory discussions and potential accelerated approval pathways. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fina","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TRDA":"Entrada Therapeutics, Inc."},"translate_title":"Entrada Therapeutics公布杜氏症和强直性肌营养不良项目的管道进展和临床里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TRDA":0.9},"content_text":"Entrada Therapeutics Unveils Pipeline Progress and Clinical Milestones for Duchenne and Myotonic Dystrophy Programs\n    \n\n        Entrada Therapeutics Inc. has provided an update on its clinical development pipeline, outlining plans to advance four clinical-stage programs by the end of 2025. Key milestones expected in 2026 include data readouts for ENTR-601-44 and ENTR-601-45, as well as progress on ENTR-601-50 and Vertex-partnered VX-670 for myotonic dystrophy type 1 (DM1). The company highlighted its strategy around its EEV platform, emphasizing improvements in endosomal escape and the development of novel PMO conjugates. Entrada also noted that ongoing and planned ex-U.S. studies are designed to generate data supporting future regulatory discussions and potential accelerated approval pathways. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on December 15, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591962511","isCrawlerRequest":true}